Specifically, treatment of the cells from patients with OB/T2D with 10−12 M of the compound induced a significant increment in glucose transport, with maximal effects observed at 10−11 M. This finding suggests a relevant sensitivity of cells from patients with OB/T2D to the BRS-3 ligand. Here, BRS3 is linked to type 2 diabetes mellitus.